...
首页> 外文期刊>Acta Medica Martiniana >Search for Molecular Biomarkers of Parkinson’s Disease. New Tissues and Methods
【24h】

Search for Molecular Biomarkers of Parkinson’s Disease. New Tissues and Methods

机译:搜索帕金森病的分子生物标志物。新组织和方法

获取原文
获取原文并翻译 | 示例

摘要

Abstract Parkinson’s disease (PD) is a chronic neurodegenerative disorder that is clinically manifested by motor and non-motor symptoms. At the early stage of the disease, it can be misdiagnosed with some neurologic disorders due to overlapping or similar clinical features. In addition, the pathogenesis of this disease is initiated several years prior to the appearance of classical motor symptoms. This latent phase of neurodegeneration in PD characterised at cellular level by preservation of significant fraction of dopaminergic neurones is of particular interest with respect to the development of disease-modifying or neuroprotective therapies which would require intervention at the earliest stages of disease with an aim to slow down or reverse the disease progression. Therefore, huge effort was performed in order to find and validate a biomarker that would reliably differentiate PD from other neurologic diseases as well as a biomarker that would reveal preclinical/prodromal stage of PD. This short review summarises a recent progress in validation of molecular biomarkers of PD, distinct from genetic markers of PD, with some focus on new analysed tissues and new methods.
机译:摘要 帕金森病(PD)是一种慢性神经退行性疾病,临床表现为运动和非运动症状。在疾病的早期阶段,由于重叠或相似的临床特征,它可能被误诊为某些神经系统疾病。此外,这种疾病的发病机制是在经典运动症状出现前几年开始的。帕金森病神经退行性变的潜伏期在细胞水平上以保留大量多巴胺能神经元为特征,对于开发疾病修饰或神经保护疗法特别感兴趣,这些疗法需要在疾病的早期阶段进行干预,以减缓或逆转疾病进展。因此,为了找到和验证能够可靠地将 PD 与其他神经系统疾病区分开来的生物标志物以及揭示 PD 临床前/前驱阶段的生物标志物,我们付出了巨大的努力。这篇简短的综述总结了PD分子生物标志物验证的最新进展,与PD的遗传标记不同,重点关注新的分析组织和新方法。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号